Next Article in Journal
Mitogenomic Research of Silverleaf Sunflower (Helianthus argophyllus) and Its Interspecific Hybrids
Next Article in Special Issue
Potential Diagnostic Biomarker Detection for Prostate Cancer Using Untargeted and Targeted Metabolomic Profiling
Previous Article in Journal
Molecular Detection of Nosema spp. in Three Eco Regions of Slovakia
Previous Article in Special Issue
Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas
 
 
Review
Peer-Review Record

Adenovirus as a Vector and Oncolytic Virus

Curr. Issues Mol. Biol. 2023, 45(6), 4826-4840; https://doi.org/10.3390/cimb45060307
by Wataru Matsunaga 1 and Akinobu Gotoh 2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Curr. Issues Mol. Biol. 2023, 45(6), 4826-4840; https://doi.org/10.3390/cimb45060307
Submission received: 4 May 2023 / Revised: 30 May 2023 / Accepted: 30 May 2023 / Published: 2 June 2023
(This article belongs to the Special Issue Advanced Molecular Solutions for Cancer Therapy)

Round 1

Reviewer 1 Report

In the manuscript "Adenovirus as a Vector and Oncolytic Virus" the authors speak about the importance of adenoviral vectors, oncolytic viruses, and gene delivery vectors. They focalized their attention on the new-generation adenoviral vectors, describing the modification of the fiber knob region that enhances the affinity of adenoviral vectors for cancer cells and the utilization of cancer cell-specific promoters to suppress the expression of unwanted transgenes in non-malignant tissues.

The manuscript is well-structured and organized. I would like to suggest correcting some spelling errors in the text and also the article written by Chianese et al. ( Oncolytic viruses in combination therapeutic approaches with epigenetic modulators: Past, present, and future perspectives; PMID: 34199429) to improve the quality of the manuscript.

Author Response

To Review#1

 

We wish to express our appreciation to the reviewers for their insightful comments on our paper. The comments have helped us significantly improve the paper.

 

The manuscript is well-structured and organized. I would like to suggest correcting some spelling errors in the text and also the article written by Chianese et al. ( Oncolytic viruses in combination therapeutic approaches with epigenetic modulators: Past, present, and future perspectives; PMID: 34199429) to improve the quality of the manuscript.

→We have changed British-style spellings such as "fibre" and "titre" to American-style "fiber" and "titer" as you suggested.

Reviewer 2 Report

I have read this review throughout, which mainly discusses adenovirus as a vector and oncolytic virus. Adenovirus vectors have broad application prospects in the field of biomedicine due to their significant advantages such as high loading capacity and strong oncolytic effect. The entry point of this review is good, but there is still insufficient understanding of the progress of adenoviruses., The following modifications are required:

1.      The article needs to discuss the progress of clinical trial research on adenovirus vectors (e.g. NCT04838795, NCT04152486) , which is clearly not covered in the current version.

2.      The clinical trial progress of oncolytic adenovirus and its combined application with other treatments (e.g. NCT03281382,       NCT00583492, NCT04771676) should also be extensively and deeply discussed.

 

Minor revisions:

3.      “fibre knob” appears many times in the manuscript, it should be “fiber knob”.

4.      ”“novel adenovirusbased oncolytic viruses” should be “Moreover, novel adenovirus-based oncolytic viruses”.

5.      “well-characterised” in “AAV2 is the most well-characterised and most used AAV vector.” Should be “well-characterized”.

6.      “high-titre AAV vectors is” should be “high-titer AAV vectors is”

1.     “fibre knob” appears many times in the manuscript, it should be “fiber knob”.

 

2.     ”“novel adenovirusbased oncolytic viruses” should be “Moreover, novel adenovirus-based oncolytic viruses”.

 

 

3.     “well-characterised” in “AAV2 is the most well-characterised and most used AAV vector.” Should be “well-characterized”.

 

4.     “high-titre AAV vectors is” should be “high-titer AAV vectors is”.

Author Response

To Review#2

 

We wish to express our appreciation to the reviewers for their insightful comments on our paper. The comments have helped us significantly improve the paper.

 

  1. The article needs to discuss the progress of clinical trial research on adenovirus vectors (e.g. NCT04838795, NCT04152486) , which is clearly not covered in the current version.

→We added a description of Nadofaragene firadenovec, ADV-Tk. However, since this article is the subject of adenoviral vectors for cancer therapy, the description of their use as vaccines has been kept short. (page.5, line 20-28, page.7, line 30-32)

 

  1. The clinical trial progress of oncolytic adenovirus and its combined application with other treatments (e.g. NCT03281382, NCT00583492, NCT04771676) should also be extensively and deeply discussed.

→We have added Ad5-yCD/mutTKSR39rep-ADP as an example of a "heavily armed" tumor-solving adenovirus. (page.7, line 21-27)

 

 

Minor revisions:

  1. “fibre knob” appears many times in the manuscript, it should be “fiber knob”.
  2. ”“novel adenovirusbased oncolytic viruses” should be “Moreover, novel adenovirus-based oncolytic viruses”.
  1. “well-characterised” in “AAV2 is the most well-characterised and most used AAV vector.” Should be “well-characterized”.
  1. “high-titre AAV vectors is” should be “high-titer AAV vectors is”

→We have changed “adenovirusbased” to “adenovirus-based”. Moreover, we have changed British-style spellings such as "fibre", "titre" and “charactarised” to American-style "fiber", "titer" and “characterized” as you suggested.

Back to TopTop